+关注
K_j
暂无个人介绍
IP属地：海外
6
关注
0
粉丝
0
主题
0
勋章
主贴
热门
K_j
2021-12-28
Wow
抱歉，原内容已删除
K_j
2021-12-28
Ohhh
Apple Allegedly Preparing for iPhones Without SIM Card Slot by September 2022
K_j
2021-05-06
👍👍👍
This COVID-19 Vaccine Stock Quietly Soared 75% In April: Is There More Upside Ahead?
K_j
2021-05-06
👍👍👍
This COVID-19 Vaccine Stock Quietly Soared 75% In April: Is There More Upside Ahead?
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3583246291910733","uuid":"3583246291910733","gmtCreate":1620153627549,"gmtModify":1620153627549,"name":"K_j","pinyin":"kjkj","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":6,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.31","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"海外","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":696120452,"gmtCreate":1640651883921,"gmtModify":1640651884040,"author":{"id":"3583246291910733","authorId":"3583246291910733","name":"K_j","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583246291910733","authorIdStr":"3583246291910733"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696120452","repostId":"1133233035","repostType":4,"isVote":1,"tweetType":1,"viewCount":639,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696120145,"gmtCreate":1640651839570,"gmtModify":1640651839570,"author":{"id":"3583246291910733","authorId":"3583246291910733","name":"K_j","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583246291910733","authorIdStr":"3583246291910733"},"themes":[],"htmlText":"Ohhh","listText":"Ohhh","text":"Ohhh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696120145","repostId":"1128219386","repostType":4,"repost":{"id":"1128219386","pubTimestamp":1640606013,"share":"https://www.laohu8.com/m/news/1128219386?lang=&edition=full","pubTime":"2021-12-27 19:53","market":"us","language":"en","title":"Apple Allegedly Preparing for iPhones Without SIM Card Slot by September 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1128219386","media":"MacRumors","summary":"Earlier this week, a rumor from Brazilian website Blog do iPhone claimed that iPhone 15 Pro models m","content":"<p>Earlier this week, a rumor from Brazilian website <i>Blog do iPhone</i> claimed that iPhone 15 Pro models might not have a physical SIM card slot in at least some countries and regions, but the change might happen even sooner.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/50051c321b0f16ef0e8d00f767c8e0c1\" tg-width=\"800\" tg-height=\"450\" width=\"100%\" height=\"auto\"><span>Image: iFixit</span></p>\n<p>An anonymous tipster informed<i>MacRumors</i>that Apple has advised major U.S. carriers to prepare for the launch of eSIM-only smartphones by September 2022. The tipster shared a seemingly legitimate document outlining the timeframe for this initiative, although the document does not specifically mention Apple or the iPhone.</p>\n<p>As part of the transition, some U.S. carriers will allegedly start offering select iPhone 13 models without a nano-SIM card in the box in the second quarter of 2022. iPhone 13 models sold at Apple Stores or on Apple.com already lack a nano-SIM card in the box, with users typically able to activate a cellular plan via eSIM by turning on the iPhone, connecting to a Wi-Fi network, and following the on-screen instructions.</p>\n<p>Given the alleged September 2022 deadline, it is possible that Apple might remove the physical SIM card slot starting with some iPhone 14 models, rather than some iPhone 15 models as originally rumored, but nothing is definitive at this point.</p>\n<p>An eSIM is a digital SIM that allows users to activate a cellular plan without having to use a nano-SIM card. It's worth noting that eSIM service is not available in all countries, so iPhones with a SIM card slot may remain available in some markets. Adoption is expanding rapidly, though, with over 100 carriers offering eSIM service worldwide and more planning to roll out support in 2022, including Three in the UK and Vodafone in New Zealand.</p>\n<p>iPhone 13 models already support multiple eSIM profiles, allowing users to subscribe to several cellular plans digitally and switch between them, and this functionality could pave the way for the SIM card slot's removal in select countries.</p>\n<p>Apple's former design chief Jony Ive once envisioned the iPhone as becoming a \"single slab of glass,\" and the SIM card slot's removal would be another step towards a seamless design and improve water resistance in the process. Taking out the slot would also free up some valuable internal space in the iPhone — every bit counts.</p>","source":"lsy1637734094842","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Allegedly Preparing for iPhones Without SIM Card Slot by September 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Allegedly Preparing for iPhones Without SIM Card Slot by September 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 19:53 GMT+8 <a href=https://www.macrumors.com/2021/12/26/iphones-without-sim-card-slot-2022-rumor/><strong>MacRumors</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this week, a rumor from Brazilian website Blog do iPhone claimed that iPhone 15 Pro models might not have a physical SIM card slot in at least some countries and regions, but the change might ...</p>\n\n<a href=\"https://www.macrumors.com/2021/12/26/iphones-without-sim-card-slot-2022-rumor/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.macrumors.com/2021/12/26/iphones-without-sim-card-slot-2022-rumor/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128219386","content_text":"Earlier this week, a rumor from Brazilian website Blog do iPhone claimed that iPhone 15 Pro models might not have a physical SIM card slot in at least some countries and regions, but the change might happen even sooner.\nImage: iFixit\nAn anonymous tipster informedMacRumorsthat Apple has advised major U.S. carriers to prepare for the launch of eSIM-only smartphones by September 2022. The tipster shared a seemingly legitimate document outlining the timeframe for this initiative, although the document does not specifically mention Apple or the iPhone.\nAs part of the transition, some U.S. carriers will allegedly start offering select iPhone 13 models without a nano-SIM card in the box in the second quarter of 2022. iPhone 13 models sold at Apple Stores or on Apple.com already lack a nano-SIM card in the box, with users typically able to activate a cellular plan via eSIM by turning on the iPhone, connecting to a Wi-Fi network, and following the on-screen instructions.\nGiven the alleged September 2022 deadline, it is possible that Apple might remove the physical SIM card slot starting with some iPhone 14 models, rather than some iPhone 15 models as originally rumored, but nothing is definitive at this point.\nAn eSIM is a digital SIM that allows users to activate a cellular plan without having to use a nano-SIM card. It's worth noting that eSIM service is not available in all countries, so iPhones with a SIM card slot may remain available in some markets. Adoption is expanding rapidly, though, with over 100 carriers offering eSIM service worldwide and more planning to roll out support in 2022, including Three in the UK and Vodafone in New Zealand.\niPhone 13 models already support multiple eSIM profiles, allowing users to subscribe to several cellular plans digitally and switch between them, and this functionality could pave the way for the SIM card slot's removal in select countries.\nApple's former design chief Jony Ive once envisioned the iPhone as becoming a \"single slab of glass,\" and the SIM card slot's removal would be another step towards a seamless design and improve water resistance in the process. Taking out the slot would also free up some valuable internal space in the iPhone — every bit counts.","news_type":1},"isVote":1,"tweetType":1,"viewCount":976,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":102461837,"gmtCreate":1620231897729,"gmtModify":1634206785556,"author":{"id":"3583246291910733","authorId":"3583246291910733","name":"K_j","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583246291910733","authorIdStr":"3583246291910733"},"themes":[],"htmlText":"👍👍👍","listText":"👍👍👍","text":"👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/102461837","repostId":"1131387668","repostType":4,"repost":{"id":"1131387668","pubTimestamp":1620228331,"share":"https://www.laohu8.com/m/news/1131387668?lang=&edition=full","pubTime":"2021-05-05 23:25","market":"us","language":"en","title":"This COVID-19 Vaccine Stock Quietly Soared 75% In April: Is There More Upside Ahead?","url":"https://stock-news.laohu8.com/highlight/detail?id=1131387668","media":"benzinga","summary":"Shares ofBioNTech SE, which partnered withPfizer Inc. in successfully developing a vaccine against t","content":"<p>Shares of<b>BioNTech SE</b>, which partnered with<b>Pfizer Inc.</b> in successfully developing a vaccine against the coronavirus, have been gaining ground.</p>\n<p><b>BioNTech's Price Action:</b>BioNTech and its partner Pfizerreceived in mid-Decemberauthorization for emergency use of the BNT162b2 mRNA vaccine against the novel coronavirus that causes COVID-19.</p>\n<p>BioNTech's shares, which rallied to a high of $131 ahead of the FDA decision, gave back part of the gains in a ‘buy-the-rumor, sell-the-news' move. The stock ended 2020 at $81.52, about 38% off the intraday high for the year.</p>\n<p>The German vaccine maker's stock picked up momentum early in 2021, breaching the $100 psychological resistance level on Jan. 8 and trading in a $100-$120 range until early March.</p>\n<p>The marketwide selloff in March did not spare BioNTech, with the stock dropping below $100 for a few sessions before climbing back again. The stock was locked in a lackluster phase until the end of March.</p>\n<p>Come April, the trend began to change. In the very first session of April, the stock rose over 4% and moved steadily higher through the month. In April alone, the stock added 72.4%.</p>\n<p>To put things in perspective, if an investor had invested $1,000 in BioNTech shares at the end of March, their investment would now be worth $1,909.46 (using the intraday high of $207.55 hit on Monday). This would mean nearly doubling the investment in a span of a month.</p>\n<p><b>What's Behind The BioNTech Rally:</b>The stock has been supported by the intermittent news flow regarding the company's vaccine.</p>\n<p>In late March, the companies reported positive top-line results from a study evaluating the vaccine in adolescents.</p>\n<p>On April 1, BioNTech and Pfizer reported data on BNT162b2 following six months of follow-up that confirmed its efficacy and safety.</p>\n<p>The companies announced April 9 a request to the FDA to authorize expanded use of the vaccine in adolescents ages 12-15.</p>\n<p>The FDA'sdecisionto temporarily pause the use of<b>Johnson & Johnson's</b>JNJ 0.2%vaccine also proved positive for BioNTech, which added about 7% on April 13 when the pause was announced.</p>\n<p>In mid-April, the companies announced an agreement with the European Union to supply 100 million doses of BNT162b2, which is named Comirnaty in Europe, in 2021. With that, the total number of doses delivered to the EU is 600 million.</p>\n<p>Last week, a request was submitted to the EU to expand conditional marketing authorization to adolescents in the EU.</p>\n<p><b>What Lies Ahead For BioNTech Stock?</b>BNT162b2 is expected to continue to boost BioNTech's top-line. Having delivered 200 million doses by the end of March, the company has signed orders for supplying 1.4 billion doses in 2021.</p>\n<p>Pfizer and BioNTech plan to boost the manufacturing capacity for the vaccine to 2.5 billion doses by the end of 2021.</p>\n<p>\"BioNTech and Pfizer will be the standout leader in COVID-19 vaccination globally, with demand increasing for the 2.5Bn doses they are targeting to manufacture in 2021,\" SVB Leerink analyst Daina Graybosch said in a note.</p>\n<p>With the second wave of the COVID-19 pandemic now sweeping across several nations, the companies have a lucrative opportunity. The companies have also proved the efficacy of the vaccine against variants.</p>\n<p>Once the pandemic phase passes, the vaccine has scope for use in endemic setting.</p>\n<p>More importantly, BioNTech is not a one-trick pony. The company has a broad oncology pipeline consisting of 13 product candidates.</p>\n<p>Weighing in all the opportunities, further upside in the stock cannot be ruled out.</p>\n<p><b>BNTX Price Action:</b>At last check, BioNTech shares were rising 8.2% to $191.38.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This COVID-19 Vaccine Stock Quietly Soared 75% In April: Is There More Upside Ahead?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis COVID-19 Vaccine Stock Quietly Soared 75% In April: Is There More Upside Ahead?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-05 23:25 GMT+8 <a href=https://www.benzinga.com/general/biotech/21/05/20918917/this-covid-19-vaccine-stock-quietly-soared-75-in-april-is-there-more-upside-ahead><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares ofBioNTech SE, which partnered withPfizer Inc. in successfully developing a vaccine against the coronavirus, have been gaining ground.\nBioNTech's Price Action:BioNTech and its partner ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/05/20918917/this-covid-19-vaccine-stock-quietly-soared-75-in-april-is-there-more-upside-ahead\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.benzinga.com/general/biotech/21/05/20918917/this-covid-19-vaccine-stock-quietly-soared-75-in-april-is-there-more-upside-ahead","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131387668","content_text":"Shares ofBioNTech SE, which partnered withPfizer Inc. in successfully developing a vaccine against the coronavirus, have been gaining ground.\nBioNTech's Price Action:BioNTech and its partner Pfizerreceived in mid-Decemberauthorization for emergency use of the BNT162b2 mRNA vaccine against the novel coronavirus that causes COVID-19.\nBioNTech's shares, which rallied to a high of $131 ahead of the FDA decision, gave back part of the gains in a ‘buy-the-rumor, sell-the-news' move. The stock ended 2020 at $81.52, about 38% off the intraday high for the year.\nThe German vaccine maker's stock picked up momentum early in 2021, breaching the $100 psychological resistance level on Jan. 8 and trading in a $100-$120 range until early March.\nThe marketwide selloff in March did not spare BioNTech, with the stock dropping below $100 for a few sessions before climbing back again. The stock was locked in a lackluster phase until the end of March.\nCome April, the trend began to change. In the very first session of April, the stock rose over 4% and moved steadily higher through the month. In April alone, the stock added 72.4%.\nTo put things in perspective, if an investor had invested $1,000 in BioNTech shares at the end of March, their investment would now be worth $1,909.46 (using the intraday high of $207.55 hit on Monday). This would mean nearly doubling the investment in a span of a month.\nWhat's Behind The BioNTech Rally:The stock has been supported by the intermittent news flow regarding the company's vaccine.\nIn late March, the companies reported positive top-line results from a study evaluating the vaccine in adolescents.\nOn April 1, BioNTech and Pfizer reported data on BNT162b2 following six months of follow-up that confirmed its efficacy and safety.\nThe companies announced April 9 a request to the FDA to authorize expanded use of the vaccine in adolescents ages 12-15.\nThe FDA'sdecisionto temporarily pause the use ofJohnson & Johnson'sJNJ 0.2%vaccine also proved positive for BioNTech, which added about 7% on April 13 when the pause was announced.\nIn mid-April, the companies announced an agreement with the European Union to supply 100 million doses of BNT162b2, which is named Comirnaty in Europe, in 2021. With that, the total number of doses delivered to the EU is 600 million.\nLast week, a request was submitted to the EU to expand conditional marketing authorization to adolescents in the EU.\nWhat Lies Ahead For BioNTech Stock?BNT162b2 is expected to continue to boost BioNTech's top-line. Having delivered 200 million doses by the end of March, the company has signed orders for supplying 1.4 billion doses in 2021.\nPfizer and BioNTech plan to boost the manufacturing capacity for the vaccine to 2.5 billion doses by the end of 2021.\n\"BioNTech and Pfizer will be the standout leader in COVID-19 vaccination globally, with demand increasing for the 2.5Bn doses they are targeting to manufacture in 2021,\" SVB Leerink analyst Daina Graybosch said in a note.\nWith the second wave of the COVID-19 pandemic now sweeping across several nations, the companies have a lucrative opportunity. The companies have also proved the efficacy of the vaccine against variants.\nOnce the pandemic phase passes, the vaccine has scope for use in endemic setting.\nMore importantly, BioNTech is not a one-trick pony. The company has a broad oncology pipeline consisting of 13 product candidates.\nWeighing in all the opportunities, further upside in the stock cannot be ruled out.\nBNTX Price Action:At last check, BioNTech shares were rising 8.2% to $191.38.","news_type":1},"isVote":1,"tweetType":1,"viewCount":114,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":102463726,"gmtCreate":1620231844365,"gmtModify":1634206785676,"author":{"id":"3583246291910733","authorId":"3583246291910733","name":"K_j","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583246291910733","authorIdStr":"3583246291910733"},"themes":[],"htmlText":"👍👍👍","listText":"👍👍👍","text":"👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/102463726","repostId":"1131387668","repostType":4,"repost":{"id":"1131387668","pubTimestamp":1620228331,"share":"https://www.laohu8.com/m/news/1131387668?lang=&edition=full","pubTime":"2021-05-05 23:25","market":"us","language":"en","title":"This COVID-19 Vaccine Stock Quietly Soared 75% In April: Is There More Upside Ahead?","url":"https://stock-news.laohu8.com/highlight/detail?id=1131387668","media":"benzinga","summary":"Shares ofBioNTech SE, which partnered withPfizer Inc. in successfully developing a vaccine against t","content":"<p>Shares of<b>BioNTech SE</b>, which partnered with<b>Pfizer Inc.</b> in successfully developing a vaccine against the coronavirus, have been gaining ground.</p>\n<p><b>BioNTech's Price Action:</b>BioNTech and its partner Pfizerreceived in mid-Decemberauthorization for emergency use of the BNT162b2 mRNA vaccine against the novel coronavirus that causes COVID-19.</p>\n<p>BioNTech's shares, which rallied to a high of $131 ahead of the FDA decision, gave back part of the gains in a ‘buy-the-rumor, sell-the-news' move. The stock ended 2020 at $81.52, about 38% off the intraday high for the year.</p>\n<p>The German vaccine maker's stock picked up momentum early in 2021, breaching the $100 psychological resistance level on Jan. 8 and trading in a $100-$120 range until early March.</p>\n<p>The marketwide selloff in March did not spare BioNTech, with the stock dropping below $100 for a few sessions before climbing back again. The stock was locked in a lackluster phase until the end of March.</p>\n<p>Come April, the trend began to change. In the very first session of April, the stock rose over 4% and moved steadily higher through the month. In April alone, the stock added 72.4%.</p>\n<p>To put things in perspective, if an investor had invested $1,000 in BioNTech shares at the end of March, their investment would now be worth $1,909.46 (using the intraday high of $207.55 hit on Monday). This would mean nearly doubling the investment in a span of a month.</p>\n<p><b>What's Behind The BioNTech Rally:</b>The stock has been supported by the intermittent news flow regarding the company's vaccine.</p>\n<p>In late March, the companies reported positive top-line results from a study evaluating the vaccine in adolescents.</p>\n<p>On April 1, BioNTech and Pfizer reported data on BNT162b2 following six months of follow-up that confirmed its efficacy and safety.</p>\n<p>The companies announced April 9 a request to the FDA to authorize expanded use of the vaccine in adolescents ages 12-15.</p>\n<p>The FDA'sdecisionto temporarily pause the use of<b>Johnson & Johnson's</b>JNJ 0.2%vaccine also proved positive for BioNTech, which added about 7% on April 13 when the pause was announced.</p>\n<p>In mid-April, the companies announced an agreement with the European Union to supply 100 million doses of BNT162b2, which is named Comirnaty in Europe, in 2021. With that, the total number of doses delivered to the EU is 600 million.</p>\n<p>Last week, a request was submitted to the EU to expand conditional marketing authorization to adolescents in the EU.</p>\n<p><b>What Lies Ahead For BioNTech Stock?</b>BNT162b2 is expected to continue to boost BioNTech's top-line. Having delivered 200 million doses by the end of March, the company has signed orders for supplying 1.4 billion doses in 2021.</p>\n<p>Pfizer and BioNTech plan to boost the manufacturing capacity for the vaccine to 2.5 billion doses by the end of 2021.</p>\n<p>\"BioNTech and Pfizer will be the standout leader in COVID-19 vaccination globally, with demand increasing for the 2.5Bn doses they are targeting to manufacture in 2021,\" SVB Leerink analyst Daina Graybosch said in a note.</p>\n<p>With the second wave of the COVID-19 pandemic now sweeping across several nations, the companies have a lucrative opportunity. The companies have also proved the efficacy of the vaccine against variants.</p>\n<p>Once the pandemic phase passes, the vaccine has scope for use in endemic setting.</p>\n<p>More importantly, BioNTech is not a one-trick pony. The company has a broad oncology pipeline consisting of 13 product candidates.</p>\n<p>Weighing in all the opportunities, further upside in the stock cannot be ruled out.</p>\n<p><b>BNTX Price Action:</b>At last check, BioNTech shares were rising 8.2% to $191.38.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This COVID-19 Vaccine Stock Quietly Soared 75% In April: Is There More Upside Ahead?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis COVID-19 Vaccine Stock Quietly Soared 75% In April: Is There More Upside Ahead?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-05 23:25 GMT+8 <a href=https://www.benzinga.com/general/biotech/21/05/20918917/this-covid-19-vaccine-stock-quietly-soared-75-in-april-is-there-more-upside-ahead><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares ofBioNTech SE, which partnered withPfizer Inc. in successfully developing a vaccine against the coronavirus, have been gaining ground.\nBioNTech's Price Action:BioNTech and its partner ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/05/20918917/this-covid-19-vaccine-stock-quietly-soared-75-in-april-is-there-more-upside-ahead\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.benzinga.com/general/biotech/21/05/20918917/this-covid-19-vaccine-stock-quietly-soared-75-in-april-is-there-more-upside-ahead","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131387668","content_text":"Shares ofBioNTech SE, which partnered withPfizer Inc. in successfully developing a vaccine against the coronavirus, have been gaining ground.\nBioNTech's Price Action:BioNTech and its partner Pfizerreceived in mid-Decemberauthorization for emergency use of the BNT162b2 mRNA vaccine against the novel coronavirus that causes COVID-19.\nBioNTech's shares, which rallied to a high of $131 ahead of the FDA decision, gave back part of the gains in a ‘buy-the-rumor, sell-the-news' move. The stock ended 2020 at $81.52, about 38% off the intraday high for the year.\nThe German vaccine maker's stock picked up momentum early in 2021, breaching the $100 psychological resistance level on Jan. 8 and trading in a $100-$120 range until early March.\nThe marketwide selloff in March did not spare BioNTech, with the stock dropping below $100 for a few sessions before climbing back again. The stock was locked in a lackluster phase until the end of March.\nCome April, the trend began to change. In the very first session of April, the stock rose over 4% and moved steadily higher through the month. In April alone, the stock added 72.4%.\nTo put things in perspective, if an investor had invested $1,000 in BioNTech shares at the end of March, their investment would now be worth $1,909.46 (using the intraday high of $207.55 hit on Monday). This would mean nearly doubling the investment in a span of a month.\nWhat's Behind The BioNTech Rally:The stock has been supported by the intermittent news flow regarding the company's vaccine.\nIn late March, the companies reported positive top-line results from a study evaluating the vaccine in adolescents.\nOn April 1, BioNTech and Pfizer reported data on BNT162b2 following six months of follow-up that confirmed its efficacy and safety.\nThe companies announced April 9 a request to the FDA to authorize expanded use of the vaccine in adolescents ages 12-15.\nThe FDA'sdecisionto temporarily pause the use ofJohnson & Johnson'sJNJ 0.2%vaccine also proved positive for BioNTech, which added about 7% on April 13 when the pause was announced.\nIn mid-April, the companies announced an agreement with the European Union to supply 100 million doses of BNT162b2, which is named Comirnaty in Europe, in 2021. With that, the total number of doses delivered to the EU is 600 million.\nLast week, a request was submitted to the EU to expand conditional marketing authorization to adolescents in the EU.\nWhat Lies Ahead For BioNTech Stock?BNT162b2 is expected to continue to boost BioNTech's top-line. Having delivered 200 million doses by the end of March, the company has signed orders for supplying 1.4 billion doses in 2021.\nPfizer and BioNTech plan to boost the manufacturing capacity for the vaccine to 2.5 billion doses by the end of 2021.\n\"BioNTech and Pfizer will be the standout leader in COVID-19 vaccination globally, with demand increasing for the 2.5Bn doses they are targeting to manufacture in 2021,\" SVB Leerink analyst Daina Graybosch said in a note.\nWith the second wave of the COVID-19 pandemic now sweeping across several nations, the companies have a lucrative opportunity. The companies have also proved the efficacy of the vaccine against variants.\nOnce the pandemic phase passes, the vaccine has scope for use in endemic setting.\nMore importantly, BioNTech is not a one-trick pony. The company has a broad oncology pipeline consisting of 13 product candidates.\nWeighing in all the opportunities, further upside in the stock cannot be ruled out.\nBNTX Price Action:At last check, BioNTech shares were rising 8.2% to $191.38.","news_type":1},"isVote":1,"tweetType":1,"viewCount":79,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":696120452,"gmtCreate":1640651883921,"gmtModify":1640651884040,"author":{"id":"3583246291910733","authorId":"3583246291910733","name":"K_j","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583246291910733","authorIdStr":"3583246291910733"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696120452","repostId":"1133233035","repostType":4,"repost":{"id":"1133233035","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640648898,"share":"https://www.laohu8.com/m/news/1133233035?lang=&edition=full","pubTime":"2021-12-28 07:48","market":"us","language":"en","title":"Starboard acquires stake worth $800 mln in GoDaddy","url":"https://stock-news.laohu8.com/highlight/detail?id=1133233035","media":"Reuters","summary":"Dec 27 (Reuters) - Activist investor Starboard Value LP has purchased a 6.5% stake in web services f","content":"<p>Dec 27 (Reuters) - Activist investor Starboard Value LP has purchased a 6.5% stake in web services firm GoDaddy Inc(GDDY.N)worth about $800 million, according to a regulatory filing with the U.S. Securities and Exchange Commission.</p>\n<p>Shares of GoDaddy, which have dropped 8% so far this year, rose 2.6% in premarket trading.</p>\n<p>Starboard said that GoDaddy's shares were undervalued and represented an attractive investment opportunity, according to the filing.</p>\n<p>The Wall Street Journal was the first to report the acquisition of the stake. The report also said that Starboard plans to push the company to improve its performance.</p>\n<p>Arizona-based GoDaddy has seen a surge in online traffic as several businesses increasingly shifted to digital operations due to the COVID-19 pandemic.</p>\n<p>Starboard Value and GoDaddy did not immediately respond to Reuters requests for comment.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Starboard acquires stake worth $800 mln in GoDaddy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStarboard acquires stake worth $800 mln in GoDaddy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-28 07:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 27 (Reuters) - Activist investor Starboard Value LP has purchased a 6.5% stake in web services firm GoDaddy Inc(GDDY.N)worth about $800 million, according to a regulatory filing with the U.S. Securities and Exchange Commission.</p>\n<p>Shares of GoDaddy, which have dropped 8% so far this year, rose 2.6% in premarket trading.</p>\n<p>Starboard said that GoDaddy's shares were undervalued and represented an attractive investment opportunity, according to the filing.</p>\n<p>The Wall Street Journal was the first to report the acquisition of the stake. The report also said that Starboard plans to push the company to improve its performance.</p>\n<p>Arizona-based GoDaddy has seen a surge in online traffic as several businesses increasingly shifted to digital operations due to the COVID-19 pandemic.</p>\n<p>Starboard Value and GoDaddy did not immediately respond to Reuters requests for comment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GDDY":"Godaddy Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133233035","content_text":"Dec 27 (Reuters) - Activist investor Starboard Value LP has purchased a 6.5% stake in web services firm GoDaddy Inc(GDDY.N)worth about $800 million, according to a regulatory filing with the U.S. Securities and Exchange Commission.\nShares of GoDaddy, which have dropped 8% so far this year, rose 2.6% in premarket trading.\nStarboard said that GoDaddy's shares were undervalued and represented an attractive investment opportunity, according to the filing.\nThe Wall Street Journal was the first to report the acquisition of the stake. The report also said that Starboard plans to push the company to improve its performance.\nArizona-based GoDaddy has seen a surge in online traffic as several businesses increasingly shifted to digital operations due to the COVID-19 pandemic.\nStarboard Value and GoDaddy did not immediately respond to Reuters requests for comment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":639,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696120145,"gmtCreate":1640651839570,"gmtModify":1640651839570,"author":{"id":"3583246291910733","authorId":"3583246291910733","name":"K_j","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583246291910733","authorIdStr":"3583246291910733"},"themes":[],"htmlText":"Ohhh","listText":"Ohhh","text":"Ohhh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696120145","repostId":"1128219386","repostType":4,"repost":{"id":"1128219386","pubTimestamp":1640606013,"share":"https://www.laohu8.com/m/news/1128219386?lang=&edition=full","pubTime":"2021-12-27 19:53","market":"us","language":"en","title":"Apple Allegedly Preparing for iPhones Without SIM Card Slot by September 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1128219386","media":"MacRumors","summary":"Earlier this week, a rumor from Brazilian website Blog do iPhone claimed that iPhone 15 Pro models m","content":"<p>Earlier this week, a rumor from Brazilian website <i>Blog do iPhone</i> claimed that iPhone 15 Pro models might not have a physical SIM card slot in at least some countries and regions, but the change might happen even sooner.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/50051c321b0f16ef0e8d00f767c8e0c1\" tg-width=\"800\" tg-height=\"450\" width=\"100%\" height=\"auto\"><span>Image: iFixit</span></p>\n<p>An anonymous tipster informed<i>MacRumors</i>that Apple has advised major U.S. carriers to prepare for the launch of eSIM-only smartphones by September 2022. The tipster shared a seemingly legitimate document outlining the timeframe for this initiative, although the document does not specifically mention Apple or the iPhone.</p>\n<p>As part of the transition, some U.S. carriers will allegedly start offering select iPhone 13 models without a nano-SIM card in the box in the second quarter of 2022. iPhone 13 models sold at Apple Stores or on Apple.com already lack a nano-SIM card in the box, with users typically able to activate a cellular plan via eSIM by turning on the iPhone, connecting to a Wi-Fi network, and following the on-screen instructions.</p>\n<p>Given the alleged September 2022 deadline, it is possible that Apple might remove the physical SIM card slot starting with some iPhone 14 models, rather than some iPhone 15 models as originally rumored, but nothing is definitive at this point.</p>\n<p>An eSIM is a digital SIM that allows users to activate a cellular plan without having to use a nano-SIM card. It's worth noting that eSIM service is not available in all countries, so iPhones with a SIM card slot may remain available in some markets. Adoption is expanding rapidly, though, with over 100 carriers offering eSIM service worldwide and more planning to roll out support in 2022, including Three in the UK and Vodafone in New Zealand.</p>\n<p>iPhone 13 models already support multiple eSIM profiles, allowing users to subscribe to several cellular plans digitally and switch between them, and this functionality could pave the way for the SIM card slot's removal in select countries.</p>\n<p>Apple's former design chief Jony Ive once envisioned the iPhone as becoming a \"single slab of glass,\" and the SIM card slot's removal would be another step towards a seamless design and improve water resistance in the process. Taking out the slot would also free up some valuable internal space in the iPhone — every bit counts.</p>","source":"lsy1637734094842","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Allegedly Preparing for iPhones Without SIM Card Slot by September 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Allegedly Preparing for iPhones Without SIM Card Slot by September 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 19:53 GMT+8 <a href=https://www.macrumors.com/2021/12/26/iphones-without-sim-card-slot-2022-rumor/><strong>MacRumors</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this week, a rumor from Brazilian website Blog do iPhone claimed that iPhone 15 Pro models might not have a physical SIM card slot in at least some countries and regions, but the change might ...</p>\n\n<a href=\"https://www.macrumors.com/2021/12/26/iphones-without-sim-card-slot-2022-rumor/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.macrumors.com/2021/12/26/iphones-without-sim-card-slot-2022-rumor/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128219386","content_text":"Earlier this week, a rumor from Brazilian website Blog do iPhone claimed that iPhone 15 Pro models might not have a physical SIM card slot in at least some countries and regions, but the change might happen even sooner.\nImage: iFixit\nAn anonymous tipster informedMacRumorsthat Apple has advised major U.S. carriers to prepare for the launch of eSIM-only smartphones by September 2022. The tipster shared a seemingly legitimate document outlining the timeframe for this initiative, although the document does not specifically mention Apple or the iPhone.\nAs part of the transition, some U.S. carriers will allegedly start offering select iPhone 13 models without a nano-SIM card in the box in the second quarter of 2022. iPhone 13 models sold at Apple Stores or on Apple.com already lack a nano-SIM card in the box, with users typically able to activate a cellular plan via eSIM by turning on the iPhone, connecting to a Wi-Fi network, and following the on-screen instructions.\nGiven the alleged September 2022 deadline, it is possible that Apple might remove the physical SIM card slot starting with some iPhone 14 models, rather than some iPhone 15 models as originally rumored, but nothing is definitive at this point.\nAn eSIM is a digital SIM that allows users to activate a cellular plan without having to use a nano-SIM card. It's worth noting that eSIM service is not available in all countries, so iPhones with a SIM card slot may remain available in some markets. Adoption is expanding rapidly, though, with over 100 carriers offering eSIM service worldwide and more planning to roll out support in 2022, including Three in the UK and Vodafone in New Zealand.\niPhone 13 models already support multiple eSIM profiles, allowing users to subscribe to several cellular plans digitally and switch between them, and this functionality could pave the way for the SIM card slot's removal in select countries.\nApple's former design chief Jony Ive once envisioned the iPhone as becoming a \"single slab of glass,\" and the SIM card slot's removal would be another step towards a seamless design and improve water resistance in the process. Taking out the slot would also free up some valuable internal space in the iPhone — every bit counts.","news_type":1},"isVote":1,"tweetType":1,"viewCount":976,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":102461837,"gmtCreate":1620231897729,"gmtModify":1634206785556,"author":{"id":"3583246291910733","authorId":"3583246291910733","name":"K_j","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583246291910733","authorIdStr":"3583246291910733"},"themes":[],"htmlText":"👍👍👍","listText":"👍👍👍","text":"👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/102461837","repostId":"1131387668","repostType":4,"repost":{"id":"1131387668","pubTimestamp":1620228331,"share":"https://www.laohu8.com/m/news/1131387668?lang=&edition=full","pubTime":"2021-05-05 23:25","market":"us","language":"en","title":"This COVID-19 Vaccine Stock Quietly Soared 75% In April: Is There More Upside Ahead?","url":"https://stock-news.laohu8.com/highlight/detail?id=1131387668","media":"benzinga","summary":"Shares ofBioNTech SE, which partnered withPfizer Inc. in successfully developing a vaccine against t","content":"<p>Shares of<b>BioNTech SE</b>, which partnered with<b>Pfizer Inc.</b> in successfully developing a vaccine against the coronavirus, have been gaining ground.</p>\n<p><b>BioNTech's Price Action:</b>BioNTech and its partner Pfizerreceived in mid-Decemberauthorization for emergency use of the BNT162b2 mRNA vaccine against the novel coronavirus that causes COVID-19.</p>\n<p>BioNTech's shares, which rallied to a high of $131 ahead of the FDA decision, gave back part of the gains in a ‘buy-the-rumor, sell-the-news' move. The stock ended 2020 at $81.52, about 38% off the intraday high for the year.</p>\n<p>The German vaccine maker's stock picked up momentum early in 2021, breaching the $100 psychological resistance level on Jan. 8 and trading in a $100-$120 range until early March.</p>\n<p>The marketwide selloff in March did not spare BioNTech, with the stock dropping below $100 for a few sessions before climbing back again. The stock was locked in a lackluster phase until the end of March.</p>\n<p>Come April, the trend began to change. In the very first session of April, the stock rose over 4% and moved steadily higher through the month. In April alone, the stock added 72.4%.</p>\n<p>To put things in perspective, if an investor had invested $1,000 in BioNTech shares at the end of March, their investment would now be worth $1,909.46 (using the intraday high of $207.55 hit on Monday). This would mean nearly doubling the investment in a span of a month.</p>\n<p><b>What's Behind The BioNTech Rally:</b>The stock has been supported by the intermittent news flow regarding the company's vaccine.</p>\n<p>In late March, the companies reported positive top-line results from a study evaluating the vaccine in adolescents.</p>\n<p>On April 1, BioNTech and Pfizer reported data on BNT162b2 following six months of follow-up that confirmed its efficacy and safety.</p>\n<p>The companies announced April 9 a request to the FDA to authorize expanded use of the vaccine in adolescents ages 12-15.</p>\n<p>The FDA'sdecisionto temporarily pause the use of<b>Johnson & Johnson's</b>JNJ 0.2%vaccine also proved positive for BioNTech, which added about 7% on April 13 when the pause was announced.</p>\n<p>In mid-April, the companies announced an agreement with the European Union to supply 100 million doses of BNT162b2, which is named Comirnaty in Europe, in 2021. With that, the total number of doses delivered to the EU is 600 million.</p>\n<p>Last week, a request was submitted to the EU to expand conditional marketing authorization to adolescents in the EU.</p>\n<p><b>What Lies Ahead For BioNTech Stock?</b>BNT162b2 is expected to continue to boost BioNTech's top-line. Having delivered 200 million doses by the end of March, the company has signed orders for supplying 1.4 billion doses in 2021.</p>\n<p>Pfizer and BioNTech plan to boost the manufacturing capacity for the vaccine to 2.5 billion doses by the end of 2021.</p>\n<p>\"BioNTech and Pfizer will be the standout leader in COVID-19 vaccination globally, with demand increasing for the 2.5Bn doses they are targeting to manufacture in 2021,\" SVB Leerink analyst Daina Graybosch said in a note.</p>\n<p>With the second wave of the COVID-19 pandemic now sweeping across several nations, the companies have a lucrative opportunity. The companies have also proved the efficacy of the vaccine against variants.</p>\n<p>Once the pandemic phase passes, the vaccine has scope for use in endemic setting.</p>\n<p>More importantly, BioNTech is not a one-trick pony. The company has a broad oncology pipeline consisting of 13 product candidates.</p>\n<p>Weighing in all the opportunities, further upside in the stock cannot be ruled out.</p>\n<p><b>BNTX Price Action:</b>At last check, BioNTech shares were rising 8.2% to $191.38.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This COVID-19 Vaccine Stock Quietly Soared 75% In April: Is There More Upside Ahead?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis COVID-19 Vaccine Stock Quietly Soared 75% In April: Is There More Upside Ahead?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-05 23:25 GMT+8 <a href=https://www.benzinga.com/general/biotech/21/05/20918917/this-covid-19-vaccine-stock-quietly-soared-75-in-april-is-there-more-upside-ahead><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares ofBioNTech SE, which partnered withPfizer Inc. in successfully developing a vaccine against the coronavirus, have been gaining ground.\nBioNTech's Price Action:BioNTech and its partner ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/05/20918917/this-covid-19-vaccine-stock-quietly-soared-75-in-april-is-there-more-upside-ahead\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.benzinga.com/general/biotech/21/05/20918917/this-covid-19-vaccine-stock-quietly-soared-75-in-april-is-there-more-upside-ahead","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131387668","content_text":"Shares ofBioNTech SE, which partnered withPfizer Inc. in successfully developing a vaccine against the coronavirus, have been gaining ground.\nBioNTech's Price Action:BioNTech and its partner Pfizerreceived in mid-Decemberauthorization for emergency use of the BNT162b2 mRNA vaccine against the novel coronavirus that causes COVID-19.\nBioNTech's shares, which rallied to a high of $131 ahead of the FDA decision, gave back part of the gains in a ‘buy-the-rumor, sell-the-news' move. The stock ended 2020 at $81.52, about 38% off the intraday high for the year.\nThe German vaccine maker's stock picked up momentum early in 2021, breaching the $100 psychological resistance level on Jan. 8 and trading in a $100-$120 range until early March.\nThe marketwide selloff in March did not spare BioNTech, with the stock dropping below $100 for a few sessions before climbing back again. The stock was locked in a lackluster phase until the end of March.\nCome April, the trend began to change. In the very first session of April, the stock rose over 4% and moved steadily higher through the month. In April alone, the stock added 72.4%.\nTo put things in perspective, if an investor had invested $1,000 in BioNTech shares at the end of March, their investment would now be worth $1,909.46 (using the intraday high of $207.55 hit on Monday). This would mean nearly doubling the investment in a span of a month.\nWhat's Behind The BioNTech Rally:The stock has been supported by the intermittent news flow regarding the company's vaccine.\nIn late March, the companies reported positive top-line results from a study evaluating the vaccine in adolescents.\nOn April 1, BioNTech and Pfizer reported data on BNT162b2 following six months of follow-up that confirmed its efficacy and safety.\nThe companies announced April 9 a request to the FDA to authorize expanded use of the vaccine in adolescents ages 12-15.\nThe FDA'sdecisionto temporarily pause the use ofJohnson & Johnson'sJNJ 0.2%vaccine also proved positive for BioNTech, which added about 7% on April 13 when the pause was announced.\nIn mid-April, the companies announced an agreement with the European Union to supply 100 million doses of BNT162b2, which is named Comirnaty in Europe, in 2021. With that, the total number of doses delivered to the EU is 600 million.\nLast week, a request was submitted to the EU to expand conditional marketing authorization to adolescents in the EU.\nWhat Lies Ahead For BioNTech Stock?BNT162b2 is expected to continue to boost BioNTech's top-line. Having delivered 200 million doses by the end of March, the company has signed orders for supplying 1.4 billion doses in 2021.\nPfizer and BioNTech plan to boost the manufacturing capacity for the vaccine to 2.5 billion doses by the end of 2021.\n\"BioNTech and Pfizer will be the standout leader in COVID-19 vaccination globally, with demand increasing for the 2.5Bn doses they are targeting to manufacture in 2021,\" SVB Leerink analyst Daina Graybosch said in a note.\nWith the second wave of the COVID-19 pandemic now sweeping across several nations, the companies have a lucrative opportunity. The companies have also proved the efficacy of the vaccine against variants.\nOnce the pandemic phase passes, the vaccine has scope for use in endemic setting.\nMore importantly, BioNTech is not a one-trick pony. The company has a broad oncology pipeline consisting of 13 product candidates.\nWeighing in all the opportunities, further upside in the stock cannot be ruled out.\nBNTX Price Action:At last check, BioNTech shares were rising 8.2% to $191.38.","news_type":1},"isVote":1,"tweetType":1,"viewCount":114,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":102463726,"gmtCreate":1620231844365,"gmtModify":1634206785676,"author":{"id":"3583246291910733","authorId":"3583246291910733","name":"K_j","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583246291910733","authorIdStr":"3583246291910733"},"themes":[],"htmlText":"👍👍👍","listText":"👍👍👍","text":"👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/102463726","repostId":"1131387668","repostType":4,"repost":{"id":"1131387668","pubTimestamp":1620228331,"share":"https://www.laohu8.com/m/news/1131387668?lang=&edition=full","pubTime":"2021-05-05 23:25","market":"us","language":"en","title":"This COVID-19 Vaccine Stock Quietly Soared 75% In April: Is There More Upside Ahead?","url":"https://stock-news.laohu8.com/highlight/detail?id=1131387668","media":"benzinga","summary":"Shares ofBioNTech SE, which partnered withPfizer Inc. in successfully developing a vaccine against t","content":"<p>Shares of<b>BioNTech SE</b>, which partnered with<b>Pfizer Inc.</b> in successfully developing a vaccine against the coronavirus, have been gaining ground.</p>\n<p><b>BioNTech's Price Action:</b>BioNTech and its partner Pfizerreceived in mid-Decemberauthorization for emergency use of the BNT162b2 mRNA vaccine against the novel coronavirus that causes COVID-19.</p>\n<p>BioNTech's shares, which rallied to a high of $131 ahead of the FDA decision, gave back part of the gains in a ‘buy-the-rumor, sell-the-news' move. The stock ended 2020 at $81.52, about 38% off the intraday high for the year.</p>\n<p>The German vaccine maker's stock picked up momentum early in 2021, breaching the $100 psychological resistance level on Jan. 8 and trading in a $100-$120 range until early March.</p>\n<p>The marketwide selloff in March did not spare BioNTech, with the stock dropping below $100 for a few sessions before climbing back again. The stock was locked in a lackluster phase until the end of March.</p>\n<p>Come April, the trend began to change. In the very first session of April, the stock rose over 4% and moved steadily higher through the month. In April alone, the stock added 72.4%.</p>\n<p>To put things in perspective, if an investor had invested $1,000 in BioNTech shares at the end of March, their investment would now be worth $1,909.46 (using the intraday high of $207.55 hit on Monday). This would mean nearly doubling the investment in a span of a month.</p>\n<p><b>What's Behind The BioNTech Rally:</b>The stock has been supported by the intermittent news flow regarding the company's vaccine.</p>\n<p>In late March, the companies reported positive top-line results from a study evaluating the vaccine in adolescents.</p>\n<p>On April 1, BioNTech and Pfizer reported data on BNT162b2 following six months of follow-up that confirmed its efficacy and safety.</p>\n<p>The companies announced April 9 a request to the FDA to authorize expanded use of the vaccine in adolescents ages 12-15.</p>\n<p>The FDA'sdecisionto temporarily pause the use of<b>Johnson & Johnson's</b>JNJ 0.2%vaccine also proved positive for BioNTech, which added about 7% on April 13 when the pause was announced.</p>\n<p>In mid-April, the companies announced an agreement with the European Union to supply 100 million doses of BNT162b2, which is named Comirnaty in Europe, in 2021. With that, the total number of doses delivered to the EU is 600 million.</p>\n<p>Last week, a request was submitted to the EU to expand conditional marketing authorization to adolescents in the EU.</p>\n<p><b>What Lies Ahead For BioNTech Stock?</b>BNT162b2 is expected to continue to boost BioNTech's top-line. Having delivered 200 million doses by the end of March, the company has signed orders for supplying 1.4 billion doses in 2021.</p>\n<p>Pfizer and BioNTech plan to boost the manufacturing capacity for the vaccine to 2.5 billion doses by the end of 2021.</p>\n<p>\"BioNTech and Pfizer will be the standout leader in COVID-19 vaccination globally, with demand increasing for the 2.5Bn doses they are targeting to manufacture in 2021,\" SVB Leerink analyst Daina Graybosch said in a note.</p>\n<p>With the second wave of the COVID-19 pandemic now sweeping across several nations, the companies have a lucrative opportunity. The companies have also proved the efficacy of the vaccine against variants.</p>\n<p>Once the pandemic phase passes, the vaccine has scope for use in endemic setting.</p>\n<p>More importantly, BioNTech is not a one-trick pony. The company has a broad oncology pipeline consisting of 13 product candidates.</p>\n<p>Weighing in all the opportunities, further upside in the stock cannot be ruled out.</p>\n<p><b>BNTX Price Action:</b>At last check, BioNTech shares were rising 8.2% to $191.38.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This COVID-19 Vaccine Stock Quietly Soared 75% In April: Is There More Upside Ahead?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis COVID-19 Vaccine Stock Quietly Soared 75% In April: Is There More Upside Ahead?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-05 23:25 GMT+8 <a href=https://www.benzinga.com/general/biotech/21/05/20918917/this-covid-19-vaccine-stock-quietly-soared-75-in-april-is-there-more-upside-ahead><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares ofBioNTech SE, which partnered withPfizer Inc. in successfully developing a vaccine against the coronavirus, have been gaining ground.\nBioNTech's Price Action:BioNTech and its partner ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/05/20918917/this-covid-19-vaccine-stock-quietly-soared-75-in-april-is-there-more-upside-ahead\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.benzinga.com/general/biotech/21/05/20918917/this-covid-19-vaccine-stock-quietly-soared-75-in-april-is-there-more-upside-ahead","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131387668","content_text":"Shares ofBioNTech SE, which partnered withPfizer Inc. in successfully developing a vaccine against the coronavirus, have been gaining ground.\nBioNTech's Price Action:BioNTech and its partner Pfizerreceived in mid-Decemberauthorization for emergency use of the BNT162b2 mRNA vaccine against the novel coronavirus that causes COVID-19.\nBioNTech's shares, which rallied to a high of $131 ahead of the FDA decision, gave back part of the gains in a ‘buy-the-rumor, sell-the-news' move. The stock ended 2020 at $81.52, about 38% off the intraday high for the year.\nThe German vaccine maker's stock picked up momentum early in 2021, breaching the $100 psychological resistance level on Jan. 8 and trading in a $100-$120 range until early March.\nThe marketwide selloff in March did not spare BioNTech, with the stock dropping below $100 for a few sessions before climbing back again. The stock was locked in a lackluster phase until the end of March.\nCome April, the trend began to change. In the very first session of April, the stock rose over 4% and moved steadily higher through the month. In April alone, the stock added 72.4%.\nTo put things in perspective, if an investor had invested $1,000 in BioNTech shares at the end of March, their investment would now be worth $1,909.46 (using the intraday high of $207.55 hit on Monday). This would mean nearly doubling the investment in a span of a month.\nWhat's Behind The BioNTech Rally:The stock has been supported by the intermittent news flow regarding the company's vaccine.\nIn late March, the companies reported positive top-line results from a study evaluating the vaccine in adolescents.\nOn April 1, BioNTech and Pfizer reported data on BNT162b2 following six months of follow-up that confirmed its efficacy and safety.\nThe companies announced April 9 a request to the FDA to authorize expanded use of the vaccine in adolescents ages 12-15.\nThe FDA'sdecisionto temporarily pause the use ofJohnson & Johnson'sJNJ 0.2%vaccine also proved positive for BioNTech, which added about 7% on April 13 when the pause was announced.\nIn mid-April, the companies announced an agreement with the European Union to supply 100 million doses of BNT162b2, which is named Comirnaty in Europe, in 2021. With that, the total number of doses delivered to the EU is 600 million.\nLast week, a request was submitted to the EU to expand conditional marketing authorization to adolescents in the EU.\nWhat Lies Ahead For BioNTech Stock?BNT162b2 is expected to continue to boost BioNTech's top-line. Having delivered 200 million doses by the end of March, the company has signed orders for supplying 1.4 billion doses in 2021.\nPfizer and BioNTech plan to boost the manufacturing capacity for the vaccine to 2.5 billion doses by the end of 2021.\n\"BioNTech and Pfizer will be the standout leader in COVID-19 vaccination globally, with demand increasing for the 2.5Bn doses they are targeting to manufacture in 2021,\" SVB Leerink analyst Daina Graybosch said in a note.\nWith the second wave of the COVID-19 pandemic now sweeping across several nations, the companies have a lucrative opportunity. The companies have also proved the efficacy of the vaccine against variants.\nOnce the pandemic phase passes, the vaccine has scope for use in endemic setting.\nMore importantly, BioNTech is not a one-trick pony. The company has a broad oncology pipeline consisting of 13 product candidates.\nWeighing in all the opportunities, further upside in the stock cannot be ruled out.\nBNTX Price Action:At last check, BioNTech shares were rising 8.2% to $191.38.","news_type":1},"isVote":1,"tweetType":1,"viewCount":79,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
